


JOSH GREEN, M.D.  
GOVERNOR OF HAWAII  
KE KIA'AINA O KA MOKU'AINA 'O HAWAII



KENNETH S. FINK, MD, MGA, MPH  
DIRECTOR OF HEALTH  
KA LUNA HO'OKELE

STATE OF HAWAII  
DEPARTMENT OF HEALTH  
KA 'OIHANA OLAKINO  
P. O. BOX 3378  
HONOLULU, HI 96801-3378

In reply, please refer to:  
File:

## Hawai'i List of Equivalent Generic Drug Products and Interchangeable Biological Products

May 29, 2026

Dear Pharmacy Stakeholders:

The Hawai'i State Department of Health Food and Drug Branch (FDB) has adopted the therapeutically equivalent generic drugs approved by the [U.S. Food and Drug Administration \(FDA\)](#) and listed in the FDA's [2026 Approved Drug Products with Therapeutic Equivalence Evaluations \(Orange Book\), 46th Edition](#), including [Cumulative Supplement 4 \(April 2026\)](#).

FDB has also adopted FDA's [List of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations \(Purple Book\)](#), which includes the [May 2026](#) update to the [Purple Book Database of Licensed Biological Products](#). The Purple Book database contains information on all FDA-licensed (approved) biological products regulated by the Center for Drug Evaluation and Research (CDER), including licensed biosimilar and interchangeable products, and their reference products. The Purple Book also contains information about all FDA-licensed allergenic, cellular, gene therapy, hematologic, and vaccine products regulated by the Center for Biologics Evaluation and Research (CBER).

By adopting the above, this letter serves as notification that Hawai'i pharmacists may substitute in accordance with Hawaii Revised Statutes (HRS) [§328-92](#) and [§328-96](#).

Hawai'i State Department of Health  
Food and Drug Branch

Email: [doh.fdbinfo@doh.hawaii.gov](mailto:doh.fdbinfo@doh.hawaii.gov)